Limits...
Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.

Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, Nanjo S, Fujinami H, Nishikawa J, Ogawa K, Nakajima T, Imura J, Sugiyama T - Gastroenterol Res Pract (2015)

Bottom Line: Methods.Conclusion.Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, Japan.

ABSTRACT
Objective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods. Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results. Eight males and two females (median age, 67 years (range, 52-78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n = 7, 70%), cisplatin plus etoposide (n = 2, 20%), and carboplatin plus etoposide (n = 1, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion. Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

No MeSH data available.


Related in: MedlinePlus

The median PFS and OS of study individuals.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4493294&req=5

fig1: The median PFS and OS of study individuals.

Mentions: The dose of amrubicin was determined at each physician's discretion, and six patients received 40 mg/m2/day for 3 days every 3 weeks and four patients received 35 mg/m2/day. A total of 30 cycles of amrubicin were administered to all patients, and the median number of cycles per patient was three (range, 1–7). Because of progressive disease, four patients required discontinuation of chemotherapy after only one cycle. As a result, the median PFS in all patients was 2.6 months (95% CI, 0.7–6.2) and the median OS was 5.0 months (95% CI, 1.5–9.9) after the initiation of amrubicin therapy (Figure 1).


Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.

Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, Nanjo S, Fujinami H, Nishikawa J, Ogawa K, Nakajima T, Imura J, Sugiyama T - Gastroenterol Res Pract (2015)

The median PFS and OS of study individuals.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4493294&req=5

fig1: The median PFS and OS of study individuals.
Mentions: The dose of amrubicin was determined at each physician's discretion, and six patients received 40 mg/m2/day for 3 days every 3 weeks and four patients received 35 mg/m2/day. A total of 30 cycles of amrubicin were administered to all patients, and the median number of cycles per patient was three (range, 1–7). Because of progressive disease, four patients required discontinuation of chemotherapy after only one cycle. As a result, the median PFS in all patients was 2.6 months (95% CI, 0.7–6.2) and the median OS was 5.0 months (95% CI, 1.5–9.9) after the initiation of amrubicin therapy (Figure 1).

Bottom Line: Methods.Conclusion.Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, Japan.

ABSTRACT
Objective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods. Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results. Eight males and two females (median age, 67 years (range, 52-78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n = 7, 70%), cisplatin plus etoposide (n = 2, 20%), and carboplatin plus etoposide (n = 1, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion. Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

No MeSH data available.


Related in: MedlinePlus